Thromb Haemost 2004; 91(06): 1065-1077
DOI: 10.1160/TH04-02-0064
Review Article
Schattauer GmbH

New nonlipid effects of statins and their clinical relevance in cardiovascular disease

Anetta Undas
1   Department of Medicine, Jagiellonian University School of Medicine, Krakow, Poland
,
Magdalena Celińska-Löwenhoff
1   Department of Medicine, Jagiellonian University School of Medicine, Krakow, Poland
,
Marcin Kaczor
1   Department of Medicine, Jagiellonian University School of Medicine, Krakow, Poland
,
Jacek Musial
1   Department of Medicine, Jagiellonian University School of Medicine, Krakow, Poland
› Author Affiliations
Further Information

Publication History

Received 04 February 2004

Accepted after revision 29 March 2004

Publication Date:
02 December 2017 (online)

Zoom Image

Summary

Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase, statins, have been demonstrated to reduce cardiovascular morbidity and mortality in patients with a wide range of cholesterol levels. Numerous cholesterol-independent effects of statins that may limit atherosclerosis are probably related to inhibition of the geranylgeranylation of GTP-binding intracellular signaling proteins and involve: improved vasoreactivity, mostly through increased NO bioavailability; decreased expression of proinflammatory cytokines (interleukin-6, interleukin-1β, tumor necrosis factor α), C-reactive protein, chemokines, matrix metalloproteinases, and tissue factor with the subsequent inhibition of thrombin generation; reduced platelet activity; increased thrombomodulin expression; enhanced fibrinolysis, regulation of angiogenesis and immunomodulation. However, the clinical relevance of multiple protective effects induced by statins has not been clarified yet.